Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

HISTORICAL FACTS: John vandermosten | History Defined

ALLR: A Precision Undertaking

By John Vandermosten, CFA NASDAQ:ALLR READ THE FULL ALLR RESEARCH REPORT

Benzinga

ACOGF: Bioequivalence Complete

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga

ALQGC: FRESH Results in November

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

TENX: The Pressure's On: Awaiting Phase 3 Start

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Benzinga

BLRX: September NDA

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

NHWK: Scorpion Grand Opening 3Q:22

By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT

Benzinga

NOVN: EPI Revenue Trends Are Strong

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

DYAI: Dapibus on the Menu

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT

Benzinga

ECOR: Consistent Expansion of Distribution

By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT

Benzinga

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Benzinga

MDXG: 2Q:22 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT

Benzinga

BIOAF: FY 2022 Results and Valuation Update

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Benzinga

BCTX: New Sites Expand Bria-IMT Trial

By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT

Benzinga

ACOGF: Resolving to Move Ahead

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

GBS: GBS' Prints Are All Over It

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT

Benzinga

TLSA: Clinical Improvements for 2nd SPMS Patient

By John Vandermosten, CFA NASDAQ:TLSA Clinical Results for Second SPMS Patient

Benzinga

NOVN: First EPI Sales

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

RVPH: First Quarter Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

TENX: 1Q:22 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Benzinga

LPCN: OLE Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

ACHV: First Quarter 2022 Results

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

LPCN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

ECOR: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT

Benzinga

MDXG: 1Q:22 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT

Benzinga

LTRN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Defense

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.